You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2025

Details for Patent: 11,110,074


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,110,074 protect, and when does it expire?

Patent 11,110,074 protects SILENOR and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 11,110,074
Title:Methods of improving the pharmacokinetics of doxepin
Abstract: Methods of improving the pharmacokinetics of doxepin in a patient.
Inventor(s): Casseday; Cara Baron (San Diego, CA), Ludington; Elizabeth (San Diego, CA), Skinner; Michael (San Diego, CA), Dube; Susan E. (Carlsbad, CA), Rogowski; Roberta L. (Rancho Santa Fe, CA), Jochelson; Philip (San Diego, CA), Mansbach; Robert (San Diego, CA)
Assignee: Currax Pharmaceuticals LLC (Brentwood, TN)
Application Number:16/876,492
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 11,110,074: A Comprehensive Analysis

Introduction

When analyzing a patent, particularly one like United States Patent 11,110,074, it is crucial to delve into its scope, claims, and the broader patent landscape. This analysis will help in understanding the patent's validity, potential for litigation, and its impact on the industry.

Patent Scope and Claims

What is Patent Scope?

Patent scope refers to the breadth and depth of protection granted by a patent. It is often measured using metrics such as independent claim length and independent claim count[3].

Analyzing Patent Claims

To understand the scope of a patent, one must carefully examine its claims. Claims are the legal definitions of the invention and define the boundaries of the patentee's rights. Here are some key aspects to consider:

Independent Claims

Independent claims stand alone and do not rely on other claims. They are crucial in defining the invention and its scope. For example, if a patent has a long independent claim, it may indicate a broader scope, but it could also be more vulnerable to challenges due to its complexity[3].

Dependent Claims

Dependent claims build upon independent claims and further narrow down the invention. They often provide additional details or limitations that can help in defending the patent against invalidity challenges.

Case Study: Patent 11,110,074

While the specific details of Patent 11,110,074 are not provided here, a thorough analysis would involve:

  • Claim Construction: Understanding the language and limitations of each claim.
  • Claim Dependency: Identifying how dependent claims relate to independent claims.
  • Scope Metrics: Using metrics like claim length and count to assess the patent's breadth and potential vulnerabilities[3].

Patent Landscape and Industry Context

Current Trends in Patent Litigation

The landscape of patent litigation has seen significant changes in recent years. For instance, the Leahy-Smith America Invents Act (AIA) of 2011 introduced several reforms that have impacted patent litigation. The number of patent infringement lawsuits increased significantly around the time of the AIA's implementation, partly due to the anticipation of changes in the law[1].

Role of Nonpracticing Entities (NPEs)

Nonpracticing entities (NPEs), often referred to as "patent trolls," play a significant role in patent litigation. They bring about a fifth of all patent infringement lawsuits, which can significantly affect the industry by increasing litigation costs and potentially stifling innovation[1].

Software-Related Patents

Software-related patents have been a major contributor to the increase in patent litigation. These patents often involve complex technologies and can lead to broader and more contentious claims[1].

Judicial Developments and Their Impact

Court Decisions and Patent Validity

Court decisions can significantly impact the validity and scope of patents. For example, the case of Allergan USA, Inc. v. MSN Laboratories Private Ltd. highlights the complexities of patent validity, particularly in the context of obviousness-type double patenting and written description requirements[2].

Doctrine of Obviousness-Type Double Patenting

This doctrine can invalidate claims if they are not patentably distinct from earlier claims. The Allergan case illustrates how this doctrine can be applied and the importance of claim construction in determining patent validity[2].

Actions by the U.S. Patent and Trademark Office (USPTO)

Improving Patent Quality

The USPTO has taken several initiatives to improve patent quality, including working with industries to develop uniform terminology and analyzing trends in patent litigation. However, there is still room for improvement, such as linking litigation data to the patent examination process to expose patterns that could enhance patent quality[1].

Global Dossier and Public Search Facilities

Tools like the Global Dossier and Public Search Facilities provided by the USPTO help in accessing and analyzing patent data. These resources can be invaluable in understanding the patent landscape and conducting thorough searches for prior art[4].

Patent Examination Process

Narrowing Claims During Examination

The patent examination process often results in the narrowing of claims. Research has shown that narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

Impact on Patent Scope

The examination process can significantly affect the scope of a patent. Longer examination durations tend to result in narrower claims, which can impact the patent's breadth and validity[3].

Litigation and Enforcement

Defenses Against Patent Infringement

When facing patent infringement claims, defendants often rely on defenses such as invalidity, non-infringement, or unenforceability. The presumption of validity under 35 USC 282 is a critical aspect, as each claim is presumed valid unless proven otherwise[5].

Recent Litigation Trends

Recent trends in patent litigation highlight the importance of thorough claim construction and the role of judicial decisions in shaping patent law. The increase in software-related patent litigation and the activities of NPEs are key factors to consider[1].

Key Takeaways

  • Patent Scope Metrics: Independent claim length and count are crucial in assessing the breadth and potential vulnerabilities of a patent.
  • Judicial Impact: Court decisions significantly influence patent validity and scope.
  • USPTO Initiatives: The USPTO's efforts to improve patent quality and provide access to patent data are vital in the patent landscape.
  • Litigation Trends: Understanding recent trends in patent litigation, including the role of NPEs and software-related patents, is essential for navigating the patent landscape.

Frequently Asked Questions (FAQs)

Q: What are the key metrics for measuring patent scope?

A: Key metrics include independent claim length and independent claim count, which help in assessing the breadth and potential vulnerabilities of a patent[3].

Q: How has the Leahy-Smith America Invents Act (AIA) impacted patent litigation?

A: The AIA has led to an increase in patent infringement lawsuits, partly due to changes in the law that limit the number of defendants in a lawsuit and other reforms[1].

Q: What is the role of nonpracticing entities (NPEs) in patent litigation?

A: NPEs bring about a fifth of all patent infringement lawsuits, which can significantly affect the industry by increasing litigation costs and potentially stifling innovation[1].

Q: How does the USPTO improve patent quality?

A: The USPTO improves patent quality through initiatives such as working with industries to develop uniform terminology and analyzing trends in patent litigation to link with the patent examination process[1].

Q: What is the significance of the doctrine of obviousness-type double patenting?

A: This doctrine can invalidate claims if they are not patentably distinct from earlier claims, highlighting the importance of claim construction in determining patent validity[2].

Cited Sources:

  1. GAO Report: Assessing Factors That Affect Patent Infringement Litigation[1].
  2. Federal Circuit Court Decision: Allergan USA, Inc. v. MSN Laboratories Private Ltd.[2].
  3. SSRN Paper: Patent Claims and Patent Scope[3].
  4. USPTO Website: Search for patents and related services[4].
  5. US Code: 35 USC 282: Presumption of validity; defenses[5].

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 11,110,074

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
Currax SILENOR doxepin hydrochloride TABLET;ORAL 022036-001 Mar 17, 2010 AB RX Yes No ⤷  Try for Free ⤷  Try for Free TREATMENT OF INSOMNIA ⤷  Try for Free
Currax SILENOR doxepin hydrochloride TABLET;ORAL 022036-002 Mar 17, 2010 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free TREATMENT OF INSOMNIA ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 2 of 2 entries

International Family Members for US Patent 11,110,074

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Canada 2693992 ⤷  Try for Free
World Intellectual Property Organization (WIPO) 2008011150 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 2 of 2 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.